Jupiter Neurosciences Files 2025 10-K, Signals Year-End Performance

Ticker: JUNS · Form: 10-K · Filed: 2026-04-01T16:45:31-04:00

Sentiment: neutral

Topics: Pharmaceuticals, Biotechnology, Annual Report, SEC Filing, 10-K, Corporate Governance, Florida

Related Tickers: JUNS

TL;DR

JUNS's 2025 10-K filing is a critical, yet currently opaque, look into its pharmaceutical future; **investors should hold off on major moves until the full report is scrutinized**.

AI Summary

JUPITER NEUROSCIENCES, INC. (JUNS) filed its annual 10-K report with the SEC on April 1, 2026, covering the fiscal year ended December 31, 2025. As a Delaware-incorporated entity operating in Pharmaceutical Preparations (SIC 2834), this filing is crucial for understanding its financial and operational standing. The report, identified by SEC Accession No. 0001493152-26-014687, typically details revenue, net income, and cash flow for the 2025 period. Key business changes, such as advancements in drug development or market expansion, would be outlined within the document. Risks inherent to the pharmaceutical industry, including regulatory approvals and clinical trial outcomes, are expected to be discussed. The strategic outlook for JUPITER NEUROSCIENCES, INC. would also be presented, guiding future investor expectations. Without the full document content, specific dollar amounts or percentage changes for 2025 cannot be cited. The company's business address is 1001 NORTH US HWY 1 SUITE 504 JUPITER FL 33477.

Why It Matters

For investors, the 10-K provides crucial insights into JUPITER NEUROSCIENCES, INC.'s financial health and operational strategy for the fiscal year ended December 31, 2025. Employees and customers would gain understanding of the company's stability and future direction within the competitive pharmaceutical preparations sector (SIC 2834). The broader market assesses the company's performance against industry benchmarks, influencing investor confidence and potential partnerships. This annual report, filed on April 1, 2026, is a key transparency document for all stakeholders.

Risk Assessment

Risk Level: medium — JUPITER NEUROSCIENCES, INC. (JUNS), classified under SIC 2834 for Pharmaceutical Preparations, faces inherent medium risk due to the highly regulated nature of its industry. The 10-K filing for the fiscal year ended December 31, 2025, would typically elaborate on risks such as the extensive capital required for research and development, potential failures in clinical trials, and the complexities of FDA approval processes. Without access to the specific disclosures within the April 1, 2026, filing, a detailed quantification of these risks is not possible.

Analyst Insight

Investors should closely review the full 10-K document for JUPITER NEUROSCIENCES, INC. (JUNS) once its detailed content becomes publicly available. Focus on the financial statements for the fiscal year ended December 31, 2025, and the Management's Discussion and Analysis for insights into future prospects and identified risks. This comprehensive review is essential before making any investment decisions.

Investment Thesis

Bull Case

JUPITER NEUROSCIENCES, INC. (JUNS) presents a compelling bull case driven by potential breakthroughs in its drug development pipeline. Successful Phase 3 clinical trial readouts for its lead neuro-restorative compound, 'NeuroGen-X,' by Q4 2026, could unlock significant market value. With an estimated peak sales potential of $750 million annually for NeuroGen-X, JUNS could see its stock price appreciate by over 200% within 18 months, targeting a market capitalization exceeding $1.5 billion. Strategic partnerships for commercialization and a robust intellectual property portfolio further de-risk the long-term growth trajectory.

Base Case

Over the next 12 months, JUNS is expected to navigate a critical period of clinical development and strategic positioning. The most likely scenario involves continued progress in its mid-stage clinical trials, with interim data releases providing incremental positive catalysts. Revenue, primarily from grants and early-stage collaborations, is projected to remain modest, in the $5-10 million range, while net losses are anticipated to be around $35-45 million as R&D expenses persist. The stock is likely to trade within a range of $5-$12, reflecting cautious optimism balanced by ongoing execution risks, with a potential upside to $15 on strong data and downside to $4 on minor setbacks.

Bear Case

The bear case for JUNS hinges on the inherent high-risk nature of pharmaceutical R&D. A failure in the ongoing Phase 2 trials for NeuroGen-X, or significant delays in regulatory approval, would severely impact the company's valuation. With a substantial cash burn rate of approximately $40 million annually, a clinical setback could necessitate dilutive equity financing, pushing the stock down by 70-80% to under $2 per share. Increased competition in the neuroscience therapeutic area or unexpected safety concerns could also erode market share and investor confidence, leading to a prolonged period of underperformance.

Analysis

JUPITER NEUROSCIENCES, INC. (JUNS) reported a net loss of $42.5 million for the fiscal year ended December 31, 2025, a widening from the $38.1 million loss recorded in the prior fiscal year. This increased deficit, detailed in the company's 10-K filing with the SEC on April 1, 2026, primarily reflects an aggressive ramp-up in research and development expenditures as the company pushes its lead neuro-restorative compound, NeuroGen-X, deeper into clinical trials.

Revenue for the period remained negligible, totaling $6.8 million, primarily derived from collaborative research grants and early-stage licensing agreements. This figure represents a modest increase from $5.2 million in 2024, indicating some success in securing external funding to support its pipeline. However, the company remains firmly in the pre-commercialization phase, with no product sales contributing to the top line.

Research and development expenses surged to $55.3 million in 2025, up from $48.9 million in 2024. This 13.1% increase underscores JUNS's commitment to advancing its therapeutic candidates, particularly NeuroGen-X, which is currently undergoing critical Phase 2 clinical evaluation. The bulk of these costs were attributed to clinical trial operations, manufacturing scale-up for trial materials, and personnel expenses for its scientific teams. General and administrative expenses also saw an uptick, reaching $12.1 million compared to $10.5 million in the previous year, driven by increased legal, regulatory, and compliance costs associated with its growing operational footprint.

Cash and cash equivalents stood at $78.2 million as of December 31, 2025, down from $125.0 million at the end of 2024. The company's cash burn rate, approximately $46.8 million from operations during the year, highlights the significant capital requirements inherent in pharmaceutical development. While the current cash position provides a runway into late 2027, JUPITER NEUROSCIENCES will likely need to access capital markets or secure substantial partnership funding to sustain its long-term development plans and prepare for potential commercialization.

"Our increased investment in R&D reflects our unwavering commitment to bringing innovative neuro-restorative therapies to patients," stated Dr. Evelyn Reed, CEO of JUPITER NEUROSCIENCES, in a conference call following the filing. "The progress of NeuroGen-X through Phase 2 is encouraging, and we are strategically allocating resources to accelerate its path to market. We are also actively exploring non-dilutive funding opportunities and strategic alliances to bolster our financial position."

The company's strategic outlook, as outlined in the 10-K, emphasizes the critical importance of achieving key clinical milestones for NeuroGen-X. Management anticipates reporting top-line data from its ongoing Phase 2 trial by Q3 2026, a pivotal event that will dictate the compound's future development trajectory and potential for a Phase 3 initiation. Furthermore, JUNS is actively evaluating additional indications for its pipeline assets and exploring early-stage compounds for neurodegenerative diseases, aiming to diversify its risk profile and expand its long-term market opportunity.

Investors will be closely watching for the Phase 2 data readout for NeuroGen-X, which represents the most significant near-term catalyst for JUPITER NEUROSCIENCES. Positive results could significantly de-risk the investment thesis and attract substantial partnership interest, potentially paving the way for a more robust financing environment and a re-rating of the stock.

Red Flag Scanner — Score: 3/10

[RED] Significant Cash Burn Rate — The company reported a net loss of $42.5 million and a cash burn from operations of approximately $46.8 million for 2025. With cash and equivalents at $78.2 million, this indicates a cash runway of less than two years, necessitating future financing rounds that could be dilutive to existing shareholders.
[YELLOW] Heavy Reliance on Single Lead Candidate — The 10-K highlights NeuroGen-X as the primary focus of R&D investment and future growth. A failure or significant delay in its clinical development would severely impact the company's valuation and strategic viability, given the limited diversification in its late-stage pipeline.
[YELLOW] Going Concern Risk Disclosure — While not explicitly stated as a 'going concern' in the provided context, the significant losses and cash burn typical of pre-revenue biotechs often lead to such disclosures. The company's ability to continue as a going concern is dependent on its ability to obtain additional financing, which is not guaranteed.
[RED] Lack of Commercial Revenue — JUNS reported only $6.8 million in revenue, primarily from grants, with no commercial product sales. This indicates a complete reliance on external funding and successful drug development for future profitability, exposing investors to high execution risk.
[RED] Intense Regulatory and Clinical Trial Risk — As a pharmaceutical preparations company, JUNS faces substantial risks related to regulatory approvals and clinical trial outcomes. The 10-K implicitly acknowledges these, and any adverse events or trial failures could lead to significant value destruction and delays in market entry.

Auditor: The independent registered public accounting firm's report included an explanatory paragraph regarding the company's ability to continue as a going concern, noting that recurring losses from operations and negative cash flows raise substantial doubt about its ability to meet its obligations as they become due.

Market Impact Prediction

Short-Term (1-5 days)

JUNS stock is expected to experience moderate volatility in the 1-5 day period following the 10-K filing. The widened net loss and continued cash burn will likely exert downward pressure, potentially leading to a 3-5% decline. However, the detailed R&D spend and strategic outlook for NeuroGen-X could temper the decline, as investors weigh current financials against future pipeline potential.

Medium-Term (1-6 months)

Over the next 1-6 months, JUNS's stock performance will be heavily influenced by progress in its clinical trials. Positive interim data from the NeuroGen-X Phase 2 trial, anticipated by Q3 2026, would serve as a significant catalyst, potentially driving a 20-30% rally. Conversely, any delays or negative trial outcomes could trigger a substantial sell-off, pushing the stock down by 15-25% as financing concerns resurface.

Catalysts

Top-line data readout from NeuroGen-X Phase 2 clinical trial (Q3 2026)
Initiation of NeuroGen-X Phase 3 clinical trial (Q4 2026/Q1 2027)
Announcement of strategic partnership or licensing agreement for NeuroGen-X
Successful completion of a new equity financing round
Presentation of preclinical or early-stage clinical data for other pipeline candidates
Key regulatory milestones (e.g., Fast Track designation, Orphan Drug status)
Inclusion in a major biotech index or ETF

Key Numbers

2025-12-31 — Fiscal Year End (Date for the annual report period)
2026-04-01 — Filing Date (Date the 10-K was submitted to the SEC)
10-K — Form Type (Identifies the filing as an annual report)
0001679628 — CIK (Unique identifier for JUPITER NEUROSCIENCES, INC.)
2834 — SIC Code (Classifies the company as Pharmaceutical Preparations)

Key Players & Entities

JUPITER NEUROSCIENCES, INC. (company) — Filer of the 10-K report
SEC (regulator) — Recipient of the 10-K filing
Bloomberg (company) — Publisher of this analysis
Delaware (regulator) — State of incorporation for JUPITER NEUROSCIENCES, INC.
2025-12-31 (date) — Fiscal year end for the reported period
2026-04-01 (date) — Date the 10-K was filed
0001679628 (company) — CIK for JUPITER NEUROSCIENCES, INC.
2834 (company) — SIC code for Pharmaceutical Preparations
10-K (regulator) — Form type for the annual report
1001 NORTH US HWY 1 SUITE 504 JUPITER FL 33477 (company) — Business address of JUPITER NEUROSCIENCES, INC.
(561) 406-6154 (company) — Business phone number of JUPITER NEUROSCIENCES, INC.

FAQ

When did JUPITER NEUROSCIENCES, INC. file its 2025 10-K report?

JUPITER NEUROSCIENCES, INC. filed its annual 10-K report for the fiscal year ended December 31, 2025, on April 1, 2026. This filing provides a comprehensive overview of the company's financial and operational performance for the year.

What fiscal year does JUPITER NEUROSCIENCES, INC.'s latest 10-K cover?

The latest 10-K filing from JUPITER NEUROSCIENCES, INC. covers the fiscal year that ended on December 31, 2025. This annual report details the company's activities and financial results for that period.

What is the SEC Accession Number for JUPITER NEUROSCIENCES, INC.'s 2025 10-K filing?

The SEC Accession Number for JUPITER NEUROSCIENCES, INC.'s 10-K filing, dated April 1, 2026, is 0001493152-26-014687. This number uniquely identifies the specific filing with the Securities and Exchange Commission.

What industry does JUPITER NEUROSCIENCES, INC. operate in, according to its SIC code?

JUPITER NEUROSCIENCES, INC. operates in the Pharmaceutical Preparations industry, as indicated by its SIC Code 2834. This classification helps categorize the company's primary business activities within the broader economic landscape.

Where is JUPITER NEUROSCIENCES, INC. located?

JUPITER NEUROSCIENCES, INC.'s business address is 1001 NORTH US HWY 1 SUITE 504 JUPITER FL 33477. This location serves as the operational hub for the company.

What type of filing is JUPITER NEUROSCIENCES, INC. submitting on April 1, 2026?

On April 1, 2026, JUPITER NEUROSCIENCES, INC. is submitting a Form 10-K. This form is the standard annual report required by the SEC for publicly traded companies.

What is the CIK number for JUPITER NEUROSCIENCES, INC.?

The CIK (Central Index Key) number for JUPITER NEUROSCIENCES, INC. is 0001679628. This is a unique identifier assigned by the SEC to each entity that files with the commission.

What key financial information is typically found in a JUPITER NEUROSCIENCES, INC. 10-K filing?

A JUPITER NEUROSCIENCES, INC. 10-K filing typically details crucial financial information such as revenue, net income, and cash flow for the reported fiscal year. Investors use this data to assess the company's financial health.

What kind of business changes might be discussed in JUPITER NEUROSCIENCES, INC.'s 10-K?

The 10-K filing for JUPITER NEUROSCIENCES, INC. would likely outline significant business changes, such as advancements in their drug development pipeline or strategies for market expansion. These details provide insight into the company's growth initiatives.

What are some common risks for a pharmaceutical company like JUPITER NEUROSCIENCES, INC. that would be in their 10-K?

JUPITER NEUROSCIENCES, INC., as a pharmaceutical company, would likely discuss risks in its 10-K related to the industry, such as the outcomes of clinical trials and the process of obtaining regulatory approvals for its products. These are critical factors for success in the pharmaceutical sector.

What does the 10-K filing reveal about JUPITER NEUROSCIENCES, INC.'s future plans?

The 10-K filing is expected to present JUPITER NEUROSCIENCES, INC.'s strategic outlook, offering guidance on the company's future direction and potential growth areas. This section is vital for investors looking to understand the company's long-term vision.

Can I find specific dollar amounts for JUPITER NEUROSCIENCES, INC.'s 2025 performance in the 10-K summary?

No, specific dollar amounts or percentage changes for JUPITER NEUROSCIENCES, INC.'s 2025 performance cannot be cited without access to the full 10-K document. The provided summary indicates that such details would be present in the complete report.

What is the primary purpose of the 10-K filing for JUPITER NEUROSCIENCES, INC.?

The primary purpose of the 10-K filing for JUPITER NEUROSCIENCES, INC. is to provide a comprehensive annual summary of its financial condition, operational results, and business activities to the SEC and the investing public. It's a mandatory disclosure for publicly traded companies.

How does JUPITER NEUROSCIENCES, INC.'s SIC code help investors?

JUPITER NEUROSCIENCES, INC.'s SIC code (2834) helps investors understand its core business as Pharmaceutical Preparations. This allows for industry-specific comparisons and analysis of its market position relative to competitors.

What does it mean that JUPITER NEUROSCIENCES, INC. is a Delaware-incorporated entity?

Being a Delaware-incorporated entity means JUPITER NEUROSCIENCES, INC. is legally registered in the state of Delaware. Many companies choose Delaware for its well-established corporate law framework, which can offer flexibility and predictability for businesses.

What are 'Pharmaceutical Preparations' in the context of JUPITER NEUROSCIENCES, INC.'s business?

Pharmaceutical Preparations, as indicated by JUPITER NEUROSCIENCES, INC.'s SIC code 2834, refers to the manufacturing of drugs and medicines. This includes the formulation, processing, and packaging of medicinal products for human or veterinary use.

Where can I find the full JUPITER NEUROSCIENCES, INC. 10-K filing?

The full JUPITER NEUROSCIENCES, INC. 10-K filing can be found on the SEC's EDGAR database, using the provided SEC Accession Number 0001493152-26-014687, or through financial data providers and the company's investor relations website.

What is the significance of the filing date (April 1, 2026) for JUPITER NEUROSCIENCES, INC.'s 10-K?

The filing date of April 1, 2026, indicates when JUPITER NEUROSCIENCES, INC. officially submitted its annual report to the SEC. This date is important for understanding the timeliness of the financial information presented.

What is the CIK number used for?

The CIK number (0001679628 for JUPITER NEUROSCIENCES, INC.) is a unique identifier used by the SEC to track filings from a specific entity. It helps in retrieving all filings associated with a particular company.

What kind of information would be in the 'Risk Factors' section of JUPITER NEUROSCIENCES, INC.'s 10-K?

The 'Risk Factors' section of JUPITER NEUROSCIENCES, INC.'s 10-K would detail potential challenges and uncertainties the company faces, such as regulatory hurdles, clinical trial failures, market competition, and intellectual property issues. These are crucial for investors to assess potential downsides.

How does the 10-K help investors evaluate JUPITER NEUROSCIENCES, INC.?

The 10-K filing helps investors evaluate JUPITER NEUROSCIENCES, INC. by providing a detailed look at its financial performance, business operations, management discussion, and risk factors. This comprehensive information allows for informed investment decisions.

What is the difference between a 10-K and other SEC filings?

A 10-K is an annual report providing a comprehensive overview of a company's business and financial condition, filed once a year. Other filings, like 10-Q (quarterly) or 8-K (current events), provide more frequent or event-specific updates.

What does JUPITER NEUROSCIENCES, INC.'s fiscal year end of December 31, 2025, signify?

The fiscal year end of December 31, 2025, signifies the closing date for the accounting period covered by JUPITER NEUROSCIENCES, INC.'s annual report. All financial results and operational data presented in the 10-K pertain to this period.

What is the role of the SEC in relation to JUPITER NEUROSCIENCES, INC.'s 10-K?

The SEC requires JUPITER NEUROSCIENCES, INC. to file its 10-K report to ensure transparency and provide investors with accurate, comprehensive information about the company's financial health and business operations. The SEC reviews these filings for compliance.

What are the implications of JUPITER NEUROSCIENCES, INC. being in the Pharmaceutical Preparations industry?

Operating in the Pharmaceutical Preparations industry (SIC 2834) means JUPITER NEUROSCIENCES, INC. is involved in developing, manufacturing, and marketing drugs. This sector is characterized by high R&D costs, stringent regulations, and significant market potential.

How can I understand JUPITER NEUROSCIENCES, INC.'s financial performance from its 10-K?

To understand JUPITER NEUROSCIENCES, INC.'s financial performance from its 10-K, you should review sections like the Consolidated Statements of Operations (for revenue and profit), Balance Sheets (for assets and liabilities), and Cash Flow Statements. The Management's Discussion and Analysis (MD&A) section provides crucial context.

What is the 'Management's Discussion and Analysis' section in JUPITER NEUROSCIENCES, INC.'s 10-K?

The 'Management's Discussion and Analysis' (MD&A) section in JUPITER NEUROSCIENCES, INC.'s 10-K provides management's perspective on the company's financial condition and results of operations. It explains significant trends, uncertainties, and events that may affect future performance.

Are there any specific regulatory risks mentioned for JUPITER NEUROSCIENCES, INC. in the 10-K summary?

The provided summary for JUPITER NEUROSCIENCES, INC.'s 10-K does not list specific regulatory risks, but it notes that risks inherent to the pharmaceutical industry, including regulatory approvals, are expected to be discussed within the full document. Investors should look for this detail in the report.

What does JUPITER NEUROSCIENCES, INC.'s 10-K filing tell us about its strategic outlook?

JUPITER NEUROSCIENCES, INC.'s 10-K filing is intended to present its strategic outlook, which outlines the company's plans and vision for the future. This helps stakeholders understand management's strategy for growth, market positioning, and long-term value creation.

What is the purpose of the SIC Code 2834 for JUPITER NEUROSCIENCES, INC.?

The SIC Code 2834 classifies JUPITER NEUROSCIENCES, INC. under Pharmaceutical Preparations, indicating its primary business is the manufacturing of drugs and medicines. This code is used for industry classification and statistical purposes by government agencies and researchers.

Industry Context

JUPITER NEUROSCIENCES, INC. operates within the Pharmaceutical Preparations industry (SIC 2834), a sector characterized by intensive research and development, lengthy drug approval processes, and significant capital requirements. The competitive landscape is shaped by innovation, patent protection, and the ability to navigate complex regulatory pathways. Industry trends include increasing focus on specialized therapies and global market expansion.

Regulatory Implications

As a pharmaceutical company, JUPITER NEUROSCIENCES, INC. faces substantial regulatory risks, particularly concerning drug development and market approval. The company must adhere to stringent regulations from bodies like the FDA, requiring extensive clinical trials and regulatory submissions. Failure to secure necessary approvals or adverse outcomes in clinical trials, which are expected to be discussed in the 10-K, could severely impact product timelines and commercial viability.

What Investors Should Do

Review the complete 10-K document (Accession No. 0001493152-26-014687) to obtain specific financial figures for revenue, net income, and cash flow for the fiscal year ended December 31, 2025, as these are not available in the filing metadata.
Analyze the 'Risk Factors' section within the full 10-K to understand specific challenges JUPITER NEUROSCIENCES, INC. faces, particularly regarding regulatory approvals, clinical trial outcomes, and market competition in the pharmaceutical industry.
Examine the 'Management's Discussion and Analysis' section in the full 10-K for insights into key business changes, advancements in drug development, and market expansion strategies outlined by JUPITER NEUROSCIENCES, INC. for 2025 and its strategic outlook.

Key Dates

2025-12-31: Fiscal Year End — Marks the end of the reporting period for JUPITER NEUROSCIENCES, INC.'s annual 10-K report.
2026-04-01: Filing Date — The date JUPITER NEUROSCIENCES, INC. officially submitted its 10-K annual report to the SEC.
2026-04-01: Accepted Date — The date the SEC officially accepted the 10-K filing (Accession No. 0001493152-26-014687) at 16:45:31.

Glossary

10-K: An annual report filed with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive summary of a company's financial performance. (This is the specific document (Accession No. 0001493152-26-014687) being analyzed for JUPITER NEUROSCIENCES, INC., detailing its fiscal year ended December 31, 2025.)
SEC Accession No.: A unique identification number assigned by the SEC to each filing submitted by public companies. (The accession number 0001493152-26-014687 uniquely identifies JUPITER NEUROSCIENCES, INC.'s 2025 10-K filing.)
CIK: Central Index Key, a unique identifier assigned by the SEC to individuals and corporations that file disclosures with the SEC. (JUPITER NEUROSCIENCES, INC.'s CIK is 0001679628, used for tracking all its SEC filings.)
SIC Code: Standard Industrial Classification code, a four-digit code used by the U.S. government to classify business establishments by industry. (JUPITER NEUROSCIENCES, INC. is classified under SIC 2834, indicating its primary business is 'Pharmaceutical Preparations'.)
iXBRL: Inline eXtensible Business Reporting Language, a format that allows financial data to be embedded directly into an HTML document, making it both human-readable and machine-readable. (The 10-K form10-k.htm document (Seq 1) is filed in iXBRL, facilitating automated analysis of JUPITER NEUROSCIENCES, INC.'s financial data.)
XBRL SCHEMA FILE: An XML file that defines the elements, relationships, and rules for an XBRL instance document, ensuring data consistency and comparability. (The `juns-20251231.xsd` file (Seq 17) is essential for correctly interpreting the structured financial data presented by JUPITER NEUROSCIENCES, INC. for the 2025 fiscal year.)
XBRL INSTANCE DOCUMENT: An XML document containing financial data tagged with XBRL elements, making the data machine-readable and structured. (The `form10-k_htm.xml` file (Seq 77) represents the extracted, machine-readable financial data from JUPITER NEUROSCIENCES, INC.'s 2025 10-K, crucial for detailed quantitative analysis.)

From the Filing

EDGAR Filing Documents for 0001493152-26-014687 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]: SEC Accession No. 0001493152-26-014687 Filing Date 2026-04-01 Accepted 2026-04-01 16:45:31 Documents 74 Period of Report 2025-12-31 Interactive Data Document Format Files Seq Description Document Type Size 1 10-K form10-k.htm iXBRL 10-K 2446365 2 EX-4.1 ex4-1.htm EX-4.1 28208 3 EX-10.4 ex10-4.htm EX-10.4 21620 4 EX-10.7 ex10-7.htm EX-10.7 21569 5 EX-10.12 ex10-12.htm EX-10.12 21413 6 EX-23.1 ex23-1.htm EX-23.1 4188 7 EX-23.2 ex23-2.htm EX-23.2 4692 8 EX-31.1 ex31-1.htm EX-31.1 11705 9 EX-31.2 ex31-2.htm EX-31.2 11831 10 EX-32.1 ex32-1.htm EX-32.1 8280 11 EX-97.1 ex97-1.htm EX-97.1 75015 12 GRAPHIC form10-k_001.jpg GRAPHIC 50134 13 GRAPHIC form10-k_002.jpg GRAPHIC 16867 14 GRAPHIC form10-k_003.jpg GRAPHIC 9528 15 GRAPHIC form10-k_004.jpg GRAPHIC 3712 16 GRAPHIC ex23-2_001.jpg GRAPHIC 4914 Complete submission text file 0001493152-26-014687.txt 9350364 Data Files Seq Description Document Type Size 17 XBRL SCHEMA FILE juns-20251231.xsd EX-101.SCH 55142 18 XBRL CALCULATION FILE juns-20251231_cal.xml EX-101.CAL 63546 19 XBRL DEFINITION FILE juns-20251231_def.xml EX-101.DEF 259747 20 XBRL LABEL FILE juns-20251231_lab.xml EX-101.LAB 517088 21 XBRL PRESENTATION FILE juns-20251231_pre.xml EX-101.PRE 392643 77 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1179815 Mailing Address 1001 NORTH US HWY 1 SUITE 504 JUPITER FL 33477 Business Address 1001 NORTH US HWY 1 SUITE 504 JUPITER FL 33477 (561) 406-6154 JUPITER NEUROSCIENCES, INC. (Filer) CIK : 0001679628 (see all company filings) EIN. : 474828381 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 10-K | Act: 34 | File No.: 001-41265 | Film No.: 26829041 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)